通过与国际专家合作，我们的机构建立了一个高活跃度和成功的造血干细胞移植计划，为各种良性和恶性血液病患者提供潜在治愈的治疗方式。原发性的自体干细胞移植计划为我们的机构提供了后续发展异体干细胞移植计划所需的基础设施、设备和专业知识。关键的移植工作人员接受了来自美国国立卫生研究院（NHLBI/NIH）、梅奥诊所（Mayo Clinic）、约翰霍普金斯医院（Johns Hopkins Hospital）和日本名古屋的国际移植专家培训，使他们具备了进行各种不同移植方法的专业知识，包括来自HLA相合亲属的外周血干细胞移植、无关脐血移植、半相合移植和CD34-筛选的干细胞移植。患者特征在所有组别中存在多样性。自从我们的移植计划开始以来，国家血液病研究所（NIHBT）每年进行的同种异体和自体移植数量稳步增加。截至2022年，已进行了547例移植手术，其中自体移植268例，同种异体移植279例。同种异体移植用于恶性和非恶性血液病，其中急性白血病（AL）是同种异体造血干细胞移植的最常见适应症。绝大多数接受同种异体移植的受者使用HLA相同或半相合亲属的G-CSF外周血干细胞移植物，少部分患者接受脐血移植或经CD34+筛选的外周血干细胞移植。在279例同种异体移植受者中，百日内和百日以后的死亡率分别为12.6%和26.2%。5年的总生存率和事件无进展生存率在良性和恶性亚组中分别为81%和73%，52%和48%。通过与国际移植专家合作，国家血液病研究所（NIHBT）在越南北部地区建立了最活跃的移植中心。来自低收入人群背景的患者现在可以接受多种不同的先进移植方法，这些方法造价合理，并且与良好的长期结果相关。版权所有©2023 Elsevier Inc. 保留所有权利。

Through collaboration with international experts, our institution established a highly active and successful hematopoietic stem cell transplant program, providing access to this potentially curative treatment modality for patients with a variety of benign and malignant hematological diseases. The initial development of an autologous stem cell transplant program provided our institution with the infrastructure, equipment, and expertise needed for the subsequent development of an allogeneic stem cell transplant program. Key transplant staff received training from international transplant experts at the NHLBI/NIH, the Mayo Clinic, the Johns Hopkins Hospital, and Nagoya Japan, providing them with the expertise to conduct a variety of different transplant approaches, including PBSC transplants from HLA-matched relatives, unrelated cord blood transplants, haploidentical transplants, and CD34 selected stem cell transplants. Patient characteristics were varied among all groups. The number of allogeneic and autologous transplants performed at the NIHBT has increased steadily every year since the initiation of our transplant program. By 2022, 547 transplant procedures had been performed, including 268 autologous and 279 allogeneic transplants. Allogeneic transplants were performed for both malignant and nonmalignant hematological diseases, with acute leukemia (AL) being the most common indication for allogeneic HCT. The majority of recipients undergoing allogeneic transplantation received G-CSF mobilized PBSC allografts from either HLA identical or haplo-identical relatives, with a smaller percentage of patients receiving a UCB transplant or a PBSC allograft that had been CD34+ selected. Amongst the 279 recipients of an allogeneic transplant, mortality rates within day 100 and beyond day 100 were 12.6% and 26.2% respectively. Overall survival (OS) and event-free survival at 5 years in benign and malignant subgroups were 81% and 73% vs 52% and 48% respectively. Through collaboration with international transplant experts, the National Institute of Hematology and Blood Transfusion in Hanoi has stood up the most active transplant center in the northern region of Vietnam. Patients coming from low-income financial backgrounds are now able to receive a variety of different state-of-the-art transplant approaches that are affordable and have been associated with excellent long-term outcomes.Copyright © 2023 Elsevier Inc. All rights reserved.